Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) saw its price target lowered by Citi to $7 from $9, with a Neutral rating. The company announced the initiation of a Phase 1 study for ARCT-2304, a self-amplifying mRNA-based pandemic influenza vaccine. Arcturus focuses on developing therapies and vaccines for rare and infectious diseases.

Investors are waiting for clinical results to determine ARCT’s future. While the company’s RNA platform shows promise, AI stocks may offer greater upside potential with less risk. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was founded in 2013 and is headquartered in San Diego, California.

Read more at Yahoo Finance: Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating